

Tucotuzumab

Cat. No.:	HY-P99328
CAS No.:	339986-90-2
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule ^[1] .	
In Vitro	Tucotuzumab targets tumors and stimulate an antitumor immune response via IL-2 responsive immune cells, as well as immune cells via their Fc receptor ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Tucotuzumab (75 µg; intratumoral injection; 5 daily of 15 µg (total dose of 75 µg), each in 50 µL PBS; on days 10 and 14) results in significantly greater tumor growth suppression and enhances survival ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Female Balb/c mice bearing CT26-KS colon adenocarcinoma ^[1]
	Dosage:	75 µg
	Administration:	Intratumoral injection; 5 daily of 15 µg (total dose of 75 µg), each in 50 µL PBS; on days 10 and 14
	Result:	Resulted in significantly greater tumor growth suppression and enhanced survival.

REFERENCES

[1]. Erik E Johnson, et al. Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res. 2009 Aug 1;15(15):4875-84.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA